Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.

Fineman MS, Mace KF, Diamant M, Darsow T, Cirincione BB, Booker Porter TK, Kinninger LA, Trautmann ME.

Diabetes Obes Metab. 2012 Jun;14(6):546-54. doi: 10.1111/j.1463-1326.2012.01561.x. Epub 2012 Feb 10.

PMID:
22236356
2.

GLP-1 based therapies: differential effects on fasting and postprandial glucose.

Fineman MS, Cirincione BB, Maggs D, Diamant M.

Diabetes Obes Metab. 2012 Aug;14(8):675-88. doi: 10.1111/j.1463-1326.2012.01560.x. Epub 2012 Feb 13. Review.

PMID:
22233527
3.

Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects.

Ellero C, Han J, Bhavsar S, Cirincione BB, Deyoung MB, Gray AL, Yushmanova I, Anderson PW.

Diabet Med. 2010 Oct;27(10):1168-73. doi: 10.1111/j.1464-5491.2010.03085.x.

4.

Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci.

Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Bhavnani SM, Ellis-Grosse E.

Diagn Microbiol Infect Dis. 2009 Feb;63(2):155-9. doi: 10.1016/j.diagmicrobio.2008.10.011.

PMID:
19150707
5.

Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.

Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Rubino CM, Korth-Bradley JM, Babinchak T, Ellis-Grosse E.

Diagn Microbiol Infect Dis. 2009 Jan;63(1):38-42. doi: 10.1016/j.diagmicrobio.2008.09.014.

PMID:
19073300
6.

Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.

Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2008 Jan;52(1):204-10. Epub 2007 Oct 22.

7.

Population pharmacokinetics of tigecycline in healthy volunteers.

Van Wart SA, Cirincione BB, Ludwig EA, Meagher AK, Korth-Bradley JM, Owen JS.

J Clin Pharmacol. 2007 Jun;47(6):727-37.

PMID:
17519399
8.

Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.

Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2007 Jun;51(6):1939-45. Epub 2007 Mar 12.

9.

Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.

Van Wart SA, Owen JS, Ludwig EA, Meagher AK, Korth-Bradley JM, Cirincione BB.

Antimicrob Agents Chemother. 2006 Nov;50(11):3701-7. Epub 2006 Aug 28.

10.

Challenges in the transition to model-based development.

Grasela TH, Fiedler-Kelly J, Walawander CA, Owen JS, Cirincione BB, Reitz KE, Ludwig EA, Passarell JA, Dement CW.

AAPS J. 2005 Oct 5;7(2):E488-95. Review.

11.

Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem.

Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG.

Antimicrob Agents Chemother. 2005 Sep;49(9):3944-7.

12.

Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction.

Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH.

J Antimicrob Chemother. 2003 Sep;52(3):435-40. Epub 2003 Aug 13.

PMID:
12917247

Supplemental Content

Loading ...
Support Center